MedPath

Brenner Baruch

🇮🇱Israel
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (100.0%)

Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.

Phase 2
Not yet recruiting
Conditions
Locally Advanced Rectal Cancer (LARC)
Interventions
Drug: Total neoadjuvant therapy (TNT)
First Posted Date
2025-04-23
Last Posted Date
2025-04-23
Lead Sponsor
brenner baruch
Target Recruit Count
134
Registration Number
NCT06940388
Locations
🇩🇪

Johannes Gutenberg-University Clinic, Mainz, Germany 1.Dept. Medicine, Prof. Peter R. Galle, Mainz, Germany

🇮🇱

Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

Phase 2
Recruiting
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
First Posted Date
2020-01-18
Last Posted Date
2020-01-18
Lead Sponsor
Baruch Brenner
Target Recruit Count
31
Registration Number
NCT04229459
Locations
🇮🇱

Rabin Medical Center, Petach Tikva, Israel

Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

Phase 2
Recruiting
Conditions
Rectal Cancer
Interventions
Radiation: Radiation therapy
Drug: mFOLFOX6
First Posted Date
2019-04-19
Last Posted Date
2019-04-19
Lead Sponsor
Baruch Brenner
Target Recruit Count
29
Registration Number
NCT03921684
Locations
🇮🇱

Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel

News

No news found
© Copyright 2025. All Rights Reserved by MedPath